These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
226 related articles for article (PubMed ID: 20524302)
1. Bortezomib for the treatment of de novo HLA antibody-related antibody mediated rejection. Al Meshari K Clin Transpl; 2009; ():385-6. PubMed ID: 20524302 [No Abstract] [Full Text] [Related]
2. Case presentations on two patients who received bortezomib for antibody mediated rejection at BIDMC. Pavlakis M Clin Transpl; 2009; ():343-5. PubMed ID: 20524296 [TBL] [Abstract][Full Text] [Related]
3. Bortezomib in the treatment of antibody-mediated rejection--a report of 3 cases. Mai HL; Cesbron A; Brouard S; Blanchol G; Cantarovich D; Dantal J; Hourmant M; Lino M; Meurette A; Gosselin M; Abbadie O; Soulillou JP; Giral M Clin Transpl; 2009; ():361-8. PubMed ID: 20524299 [No Abstract] [Full Text] [Related]
4. Use of bortezomib for treatment of antibody medicated rejection in kidney transplant recipients--case report. Hamawi K; Heilman RL; Mazur MJ; Chakkera HA; Mulligan DC; Moss AA; Mekeel KL; Reddy KS Clin Transpl; 2009; ():407-14. PubMed ID: 20524306 [No Abstract] [Full Text] [Related]
5. Bortezomib rescue in refractory acute humoral rejection--report of a case. Shapiro R; Basu A; Zeevi A; Lunz J; Mapara M; Randhawa P; Morgan C; Tan HP; Sharma V Clin Transpl; 2009; ():431-2. PubMed ID: 20524310 [No Abstract] [Full Text] [Related]
6. Rescue therapy for early antibody mediated rejection with a proteasome inhibitor: a case report. Manitpisitkul W; Wilson N; Cooper M; Gurk-Turner C; Hurley H; Rasetto F; KuKuruga D; Barth RN; Philosophe B Clin Transpl; 2009; ():461-3. PubMed ID: 20524315 [No Abstract] [Full Text] [Related]
7. Use of bortezomib for prevention and treatment of rejection in sensitized patients. Hartono C; Lubetzky M; Aull MJ; Saal S; Figueiro J; Kapur S; Dadhania D Clin Transpl; 2009; ():499-503. PubMed ID: 20524323 [TBL] [Abstract][Full Text] [Related]
8. Bortezomib as therapy for mixed humoral and cellular rejection: should it be first line? Lee I; Constantinescu S; Gillespie A; Swami A; Birkenbach M; Leech S; Silva P; Karachristos A; Daller JA; Sifontis NM Clin Transpl; 2009; ():425-9. PubMed ID: 20524309 [No Abstract] [Full Text] [Related]
10. Bortezomib use in chronic antibody-mediated allograft dysfunction: a report of three cases. Cooper JE; Wiseman AC; Chan L Clin Transpl; 2009; ():455-9. PubMed ID: 20524314 [No Abstract] [Full Text] [Related]
11. The fate of anti-HLA antibody among renal transplantation recipients treated with bortezomib. Lonze BE; Dagher NN; Simpkins CE; Singer AL; Segev DL; Zachary AA; Montgomery RA Clin Transpl; 2009; ():377-84. PubMed ID: 20524301 [TBL] [Abstract][Full Text] [Related]
12. The influence of bortezomib on donor specific antibody reduction in patients with antibody mediated rejection. Hardinger KL; Murillo D Clin Transpl; 2011; ():401-8. PubMed ID: 22755438 [TBL] [Abstract][Full Text] [Related]
14. Use of bortezomib as adjunctive therapy for densensitization in combined heart and kidney transplantation--a case report. Patel JK; Everly MJ; Kittleson M; Kobashigawa JA Clin Transpl; 2009; ():347-9. PubMed ID: 20524297 [No Abstract] [Full Text] [Related]
16. Bortezomib for antibody mediated rejection treatment: experience at the Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán in Mexico City. Leyva S; Marino-Vázquez LA; Reyes-Loaeza JA; Vega O; Uribe-Uribe N; Alberú J; Morales-Buenrostro LE Clin Transpl; 2009; ():369-76. PubMed ID: 20524300 [TBL] [Abstract][Full Text] [Related]
17. A summary of bortezomib use in transplantation across 29 centers. Everly MJ Clin Transpl; 2009; ():323-37. PubMed ID: 20524294 [TBL] [Abstract][Full Text] [Related]
18. Differential modulation of donor-specific antibodies after B-cell depleting therapies to cure chronic antibody mediated rejection. Touzot M; Couvrat-Desvergnes G; Castagnet S; Cesbron A; Renaudin K; Cantarovich D; Giral M Transplantation; 2015 Jan; 99(1):63-8. PubMed ID: 25029384 [TBL] [Abstract][Full Text] [Related]
19. The role of proteasome inhibition with bortezomib in the treatment of antibody-mediated rejection after kidney-only or kidney-combined organ transplantation. Flechner SM; Fatica R; Askar M; Stephany BR; Poggio E; Koo A; Banning S; Chiesa-Vottero A; Srinivas T Transplantation; 2010 Dec; 90(12):1486-92. PubMed ID: 21042239 [TBL] [Abstract][Full Text] [Related]
20. Bortezomib as an adjuvant to conventional therapy in the treatment of antibody mediated rejection (AMR): the full spectrum. Al Meshari K; Pall A; Elgamal H; Alzayer F; Altalhi M Clin Transpl; 2010; ():383-90. PubMed ID: 21696055 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]